According to our (Global Info Research) latest study, the global Latanoprost for Open-angle Glaucoma market size was valued at US$ 1083 million in 2025 and is forecast to a readjusted size of US$ 1315 million by 2032 with a CAGR of 2.8% during review period.
Latanoprost for open-angle glaucoma refers to latanoprost-based ophthalmic formulations, mainly 0.005% eye drops or ophthalmic emulsion, used to reduce elevated intraocular pressure in patients with open-angle glaucoma. Latanoprost is a prostaglandin F2α analogue and is commonly used once daily, making it suitable for long-term glaucoma management. Its upstream supply chain includes prostaglandin chiral intermediates, esterification reagents, solvents, buffer salts, preservatives or preservative-free packaging systems, purified water, LDPE ophthalmic bottles and secondary packaging materials. Downstream demand mainly comes from hospital ophthalmology departments, ophthalmic clinics, retail pharmacies, online prescription refill channels and chronic glaucoma follow-up management.
In 2025, global latanoprost for open-angle glaucoma production reached approximately 350 million units, with an average global market price is $3 per unit.
Latanoprost for open-angle glaucoma is a prostaglandin analogue used to reduce intraocular pressure in patients with open-angle glaucoma. It is mainly supplied as a 0.005% ophthalmic solution. Its mechanism is based on activation of prostaglandin FP receptors and enhancement of aqueous humor outflow, particularly through the uveoscleral pathway, thereby lowering intraocular pressure. The FDA-approved XALATAN label states that latanoprost is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, with the usual dosing regimen of one drop in the affected eye or eyes once daily in the evening.
Within open-angle glaucoma treatment, latanoprost is one of the foundational first-line intraocular-pressure-lowering therapies. Compared with beta blockers, carbonic anhydrase inhibitors, and alpha agonists, prostaglandin analogues generally offer once-daily dosing, proven pressure-lowering efficacy, relatively limited systemic adverse effects, and extensive long-term clinical experience. The NICE BNF treatment summary also lists topical prostaglandin analogues, including latanoprost, tafluprost, travoprost, and bimatoprost, as first-line treatment options for glaucoma and ocular hypertension. The AAO 2025 Primary Open-Angle Glaucoma Preferred Practice Pattern notes that a reasonable initial treatment goal for POAG patients is usually a 20%–30% reduction in IOP from baseline, with further adjustment according to disease course.
From a market-development perspective, Latanoprost for Open-angle Glaucoma has entered a mature generic-competition stage. Originator brands still retain clinical recognition and brand inertia, but market growth is increasingly driven by a larger patient base, population aging, improved diagnosis rates, long-term adherence management, and penetration in emerging markets. Because glaucoma treatment is typically long term and often lifelong, price, accessibility, ocular comfort, preservative-related ocular-surface irritation, packaging convenience, and patient adherence are becoming important competitive factors.
This report is a detailed and comprehensive analysis for global Latanoprost for Open-angle Glaucoma market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Latanoprost for Open-angle Glaucoma market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Latanoprost for Open-angle Glaucoma market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Latanoprost for Open-angle Glaucoma market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Latanoprost for Open-angle Glaucoma market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Latanoprost for Open-angle Glaucoma
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Latanoprost for Open-angle Glaucoma market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Viatris, Sandoz, Apotex, Teva, Taj Pharma, China Resources Zizhu Pharmaceutical, Thea Pharma, Bausch & Lomb Incorporated, Sun Pharma, Santen Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Latanoprost for Open-angle Glaucoma market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Brand Drug
Generic Drug
Market segment by Formulation Type
Monotherapy Ophthalmic Solution
Ophthalmic Emulsion
Others
Market segment by Sales Channel
Online
Offline
Market segment by Application
Hospital
Clinic
Other
Major players covered
Viatris
Sandoz
Apotex
Teva
Taj Pharma
China Resources Zizhu Pharmaceutical
Thea Pharma
Bausch & Lomb Incorporated
Sun Pharma
Santen Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Latanoprost for Open-angle Glaucoma product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Latanoprost for Open-angle Glaucoma, with price, sales quantity, revenue, and global market share of Latanoprost for Open-angle Glaucoma from 2021 to 2026.
Chapter 3, the Latanoprost for Open-angle Glaucoma competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Latanoprost for Open-angle Glaucoma breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Latanoprost for Open-angle Glaucoma market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Latanoprost for Open-angle Glaucoma.
Chapter 14 and 15, to describe Latanoprost for Open-angle Glaucoma sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Latanoprost for Open-angle Glaucoma. Industry analysis & Market Report on Latanoprost for Open-angle Glaucoma is a syndicated market report, published as Global Latanoprost for Open-angle Glaucoma Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Latanoprost for Open-angle Glaucoma market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.